Adults with overweight or obesity who received once-weekly ecnoglutide, a novel GLP-1 receptor agonist, had superior and ...

VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO, June 25, 2025 /PRNewswire/ -- Viking ...

DALLAS, June 20, 2025 It's only the first day of summer and record high temperatures are already being reported across much ...

The AHA says the heat and dehydration put significant stress on the heart. Certain heart medications can also heighten the ...

Corbus Pharmaceuticals Holdings' financial position is stable for now, with about two years of cash runway. Click here to ...

Alto Neuroscience’s phase 2 depression trial has missed its primary efficacy endpoint, as patients on the drug candidate fared no better on a measure of alertness and mood than their peers on placebo.

Wedbush restated their neutral rating on shares of Cogent Biosciences (NASDAQ:COGT – Free Report) in a research note ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Fintel reports that on June 17, 2025, Citigroup initiated coverage of Protagonist Therapeutics (NasdaqGM:PTGX) with a Buy ...

Transforming growth factor beta (TGFβ) is a cytokine that is secreted by various cell types, ... apoptosis and cellular homeostasis by binding to its receptor, the TGFβ type II receptor.

Background Mobility limitation is prevalent in patients with heart failure (HF), but the dose-response relationship between ...